

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

Examiner

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a valid OMB control number.				
Application Number	09/900,567			
Filing Date	July 6, 2001			
First Named Inventor	Carlos Plata-Salaman			
Group Art Unit				
Examiner Name				
Attorney Docket Number	ORT-1453			

	U.S. PATENT DOCUMENTS							
	Examiner Initials	Cite	U.S. Pate		d Code ² known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
1	w	DA	4,513,006			Maryanoff et al	04/23/4085 R	ECFIVED
	WH	DB	242,942	(,)	/ ,	-Coetenzo et al	909/07/1998	CIVED
L	ent	DE	5,387,700			Maryanoff et al	02/07/1905	JUN 8 4 2003
	cut	DD	6,07/1,537	1 /		R. Shank	06/06/2000	CENTER + AAA IAA IA
$\ \cdot\ $	KICT	DE	6,191,163		B1	S. Cottrell	02/20/2001	PENIEH 1800/2900
$\ \cdot\ $								
$\ \cdot\ $								<u> </u>
╟								
┟						•		
ľ								
_					FOR	EIGN PATENT DOCUMENTS		
	Examiner Initials	Cite No.1		atent Documer Number ⁴ Kir	nt ndCode ⁵	Name of Patentee or Applicant of Cited Document	of Cited Document	ages, Columns, Lines, where relevant passages or relevant figures appear
	~/	QF	V o	00/61139	A1)	Ortho-McNeil Pharmaceutical, inc.	10/19/2000	7
-	ut-	150	WO	00/61140	<i>J</i> (1	Ortho-McNeil Pharmacentical, Inc.	/0/ 9/2000	
-	KOF	DH	wo	99/44581	A2	Ortho-McNeil Fharmaceutical, Inc.	09/ 0/1999	//
\parallel	VOT	DI	wo	00/50020	A2 A1	University of dincinnati	08/\$1/2000	
ŀ	MAL	0.7		00//0 4 93 /	AI -	тајанан	12/2/1/2000	
\mid								

Considered Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a collection of information unless it displays a valid OMB control number.				
Application Number	09/900,567			
Filing Date	July 6, 2001			
First Named Inventor	Carlos Plata-Salaman			
Group Art Unit				
Examiner Name				
Attorney Docket Number	ORT-1453			

<u> </u>		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
we	D K	CROOKE et al. ABSTRACT, Topiramate Improves Glycemic Control Independent of Weight Loss in ob/ob Mice, diabetes, A Journal of the American Diabetes Association, Abstract Book 61 st Scientific Sessions Friday, June 22 - Tuesday June 26, 2001, 2158-PO, A513	_
KICF	DL	DEMAREST ET AL ABSTRACT Topirmate Improves Glucose Tolerance and May Improve Insulin Sensitivity in Animal Models of Type 2 Diabetes Mellitus, diabetes, A Journal of the American Diabetes Association, Abstract Book 61 st Scientific Sessions Friday, June 22 - Tuesday June 26, 2001, 1254-P, A302	
VCF	M	OSBORNE ET AL ABSTRACT Topiramate Improves Glycemic Control and Triglycerides in Animal Models 1 page The Posters were presented at the Amierican Diabetes Association Conference held June 22-26 in Philadelphia, diabetes, A Journal of the American Diabetes Association, Abstract Book 61 st Scientific Sessions Friday, June 22 - Tuesday June 26, 2001, 1255-P, A302	-
		IIIN 0 4 2003	
		JUN 2 4 2003	
			- 44
		TECH CENTER 1600/	900
			
	-		
	ļ		

Examiner	2N Dala	Date	7 - 8 - 4 >	
Signature	KK OUNGE	Considered	7 - 0 - O	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.